Literature DB >> 18294025

A case-control study of antidepressants and attempted suicide during early phase treatment of major depressive episodes.

Mark Olfson1, Steven C Marcus.   

Abstract

OBJECTIVE: To estimate the relative risk of suicide attempts in child and adult outpatients initiating antidepressants for major depressive episodes compared to those not treated with antidepressants.
METHOD: A nested matched case-control study was performed with Medicaid administrative data (January 1, 1999-December 31, 2000) of out-patients treated for a major depressive episode. Beneficiaries initiating treatment for a major depressive episode were selected, excluding those who had recently received inpatient psychiatric treatment or outpatient treatment of pregnancy, major depressive episodes, bipolar disorder, schizophrenia or other psychoses, mental retardation, dementia, or delirium or recent treatment with a mood stabilizer, antidepressant, or antipsychotic. The outcome was treatment for a suicide attempt during the first 120 days after starting treatment for a major depressive episode. Controls were matched to cases on age, sex, race/ethnicity, recent treatment of substance use disorder, severity and type of major depressive episode, and other factors. Separate analyses were performed for adults (aged 19 to 64 years) and children (aged 6 to 18 years).
RESULTS: Among children, antidepressant treatment was associated with a significant increase in suicide attempts (odds ratio [OR] = 2.08, 95% confidence interval [CI] = 1.06 to 4.10; cases, N = 51; controls, N = 239; p = .03). Among adults, antidepressant treatment was not significantly related to risk of suicide attempts (OR = 0.85, 95% CI = 0.57 to 1.28; cases, N = 185; controls, N = 893; p = .44), although among adult males, antidepressants were associated with a significant protective effect (OR = 0.32, 95% CI = 0.12 to 0.83; cases, N = 57; controls, N = 268; p = .01).
CONCLUSIONS: In these outpatients initiating treatment for a major depressive episode, antide-pressant treatment appears to be associated with an increased risk of treated suicide attempts in children and a decreased risk in adult males.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294025     DOI: 10.4088/jcp.v69n0313

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Paroxetine-induced increase in activity of locus coeruleus neurons in adolescent rats: implication of a countertherapeutic effect of an antidepressant.

Authors:  Charles Hutchison Keesor West; James Carl Ritchie; Jay Michael Weiss
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

2.  Serotoninergic effects on judgments and social learning of trustworthiness.

Authors:  Arndis Simonsen; Jørgen Scheel-Krüger; Mads Jensen; Andreas Roepstorff; Arne Møller; Chris D Frith; Daniel Campbell-Meiklejohn
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 3.  Major depressive disorder: new clinical, neurobiological, and treatment perspectives.

Authors:  David J Kupfer; Ellen Frank; Mary L Phillips
Journal:  Lancet       Date:  2011-12-19       Impact factor: 79.321

4.  Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies.

Authors:  Kuan Li; Guibao Zhou; Yan Xiao; Jiayu Gu; Qiuling Chen; Shouxia Xie; Junyan Wu
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

Review 5.  Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.

Authors:  Corrado Barbui; Eleonora Esposito; Andrea Cipriani
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

Review 6.  Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.

Authors:  Corri Black; Nara Tagiyeva-Milne; Peter Helms; Dorothy Moir
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

7.  Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.

Authors:  D M Rotroff; D G Corum; A Motsinger-Reif; O Fiehn; N Bottrel; W C Drevets; J Singh; G Salvadore; R Kaddurah-Daouk
Journal:  Transl Psychiatry       Date:  2016-09-20       Impact factor: 6.222

8.  A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial).

Authors:  Cheney J G Drew; Mark Postans; Cateno Petralia; Rachel McNamara; Philip Pallmann; Dave Gillespie; Lisa H Evans; Nils Muhlert; Mia Winter; Khalid Hamandi; William P Gray
Journal:  Pilot Feasibility Stud       Date:  2019-07-06

9.  Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.

Authors:  Christine Y Lu; Fang Zhang; Matthew D Lakoma; Jeanne M Madden; Donna Rusinak; Robert B Penfold; Gregory Simon; Brian K Ahmedani; Gregory Clarke; Enid M Hunkeler; Beth Waitzfelder; Ashli Owen-Smith; Marsha A Raebel; Rebecca Rossom; Karen J Coleman; Laurel A Copeland; Stephen B Soumerai
Journal:  BMJ       Date:  2014-06-18

10.  Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling.

Authors:  Matthew J Higgins; Xin Yan; Chirantan Chatterjee
Journal:  Res Policy       Date:  2020-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.